119 related articles for article (PubMed ID: 30508644)
21. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
[TBL] [Abstract][Full Text] [Related]
22. Prodifferentiation Activity of Novel Vitamin D₂ Analogs PRI-1916 and PRI-1917 and Their Combinations with a Plant Polyphenol in Acute Myeloid Leukemia Cells.
Nachliely M; Sharony E; Bolla NR; Kutner A; Danilenko M
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399677
[TBL] [Abstract][Full Text] [Related]
23. Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity.
Zheng R; Studzinski GP
J Cell Biochem; 2017 Jun; 118(6):1583-1589. PubMed ID: 27922189
[TBL] [Abstract][Full Text] [Related]
24. BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.
Zhou Y; Zhou J; Lu X; Tan TZ; Chng WJ
BMC Cancer; 2018 Jul; 18(1):731. PubMed ID: 29996811
[TBL] [Abstract][Full Text] [Related]
25. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
Del Poeta G; Bruno A; Del Principe MI; Venditti A; Maurillo L; Buccisano F; Stasi R; Neri B; Luciano F; Siniscalchi A; de Fabritiis P; Amadori S
Curr Cancer Drug Targets; 2008 May; 8(3):207-22. PubMed ID: 18473734
[TBL] [Abstract][Full Text] [Related]
26. Age-related changes in mitochondrial antioxidant enzyme Trx2 and TXNIP-Trx2-ASK1 signal pathways in the auditory cortex of a mimetic aging rat model: changes to Trx2 in the auditory cortex.
Sun HY; Hu YJ; Zhao XY; Zhong Y; Zeng LL; Chen XB; Yuan J; Wu J; Sun Y; Kong W; Kong WJ
FEBS J; 2015 Jul; 282(14):2758-74. PubMed ID: 25996168
[TBL] [Abstract][Full Text] [Related]
27. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
28. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.
Chromik J; Safferthal C; Serve H; Fulda S
Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825
[TBL] [Abstract][Full Text] [Related]
29. Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.
Lueck SC; Russ AC; Botzenhardt U; Schlenk RF; Zobel K; Deshayes K; Vucic D; Döhner H; Döhner K; Fulda S; Bullinger L
Oncotarget; 2016 Aug; 7(31):49539-49551. PubMed ID: 27385100
[TBL] [Abstract][Full Text] [Related]
30. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
31. HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun.
Schepers H; Geugien M; van der Toorn M; Bryantsev AL; Kampinga HH; Eggen BJ; Vellenga E
Exp Hematol; 2005 Jun; 33(6):660-70. PubMed ID: 15911090
[TBL] [Abstract][Full Text] [Related]
32. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
33. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
34. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
[TBL] [Abstract][Full Text] [Related]
35. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
[TBL] [Abstract][Full Text] [Related]
36. PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.
Ryu MJ; Han J; Kim SJ; Lee MJ; Ju X; Lee YL; Son JH; Cui J; Jang Y; Chung W; Song IC; Kweon GR; Heo JY
Oncol Rep; 2019 Nov; 42(5):2149-2158. PubMed ID: 31545464
[TBL] [Abstract][Full Text] [Related]
37. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
38. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
39. Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.
Song JH; Kim SH; Kim HJ; Hwang SY; Kim TS
Int J Oncol; 2008 Apr; 32(4):931-6. PubMed ID: 18360721
[TBL] [Abstract][Full Text] [Related]
40. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia.
Lagadinou ED; Ziros PG; Tsopra OA; Dimas K; Kokkinou D; Thanopoulou E; Karakantza M; Pantazis P; Spyridonidis A; Zoumbos NC
Leukemia; 2008 Oct; 22(10):1899-908. PubMed ID: 18650843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]